EntityQ842947· pop 13· linked from 113 articles

Celgene

Celgene Corporation is an American pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid (lenalidomide), which is used in the treatment of multiple myeloma, and also in certain anemias. The company is incorporated in Delaware, headquartered in Summit, New Jersey, and a subsidiary of Bristol Myers Squibb (BMS) since its acquisition in 2019.

Key facts

Company.name: Celgene Corporation
Company.logo: 150px
Company.type: Subsidiary
Company.industry: Biotechnology
Company.foundation: <!--
Company.defunct: Celgene is still listed as a significant subsidiary of BMS in its 2025 annual report -->
Company.parent: Bristol Myers Squibb
Company.location: Summit, New Jersey, U.S.
Company.key_people: Robert J. Hugin (executive chairman)Mark Alles (CEO)
Company.founder: Sol J. Barer
Company.products: RevlimidAbraxanePomalyst/ImnovidThalomidIdhifa
Company.revenue: $15.281 billion (2018)
Company.net_income: $4.046 billion (2018)
Company.assets: $35.480 billion (2018)
Company.equity: $6.161 billion (2018)
Company.num_employees: 8,852 (2018)

via Wikipedia infobox

Article

14 sections

Contents

History
Company origin and acquisition history
Management history
Finances
Products
Product-related history
Pipeline
Litigation
Antitrust allegations
Fraud allegations
Price increases
See also
References
External links

==History== Celgene was originally a unit of Celanese. In 1986, Celanese completed the corporate spin-off of Celgene following the merger of Celanese with American Hoechst.